Evaluation of Individualized Pain Plans for Children With Sickle Cell Disease Admitted for Vaso-occlusive Crisis at Riley Hospital for Children

dc.contributor.authorArends, Alexandria M.
dc.contributor.authorPerez, Anne
dc.contributor.authorWilder, Christina
dc.contributor.authorJacob, Seethal A.
dc.contributor.departmentPediatrics, School of Medicine
dc.date.accessioned2024-06-27T11:19:13Z
dc.date.available2024-06-27T11:19:13Z
dc.date.issued2022
dc.description.abstractObjective: Vaso-occlusive crisis (VOC) is the most common problem reported by patients with sickle cell disease (SCD). The objective of this study was to evaluate the impact of individualized pain plans in pediatric patients with SCD admitted for VOC. Methods: This was a pre- and post-study of patients with SCD admitted to Riley Hospital for Children for VOC from July 1, 2019, through July 1, 2020. The primary outcome was length of inpatient stay for VOC. Secondary outcomes included final pain score, days on scheduled opioids, days on breakthrough opioids, and average morphine milligram equivalents (MME) used per day. Results: Nine patients were included. The mean age was 16 years (range, 10-20 years). Key clinical findings were decreases in median [IQR] for final pain scores (7 [4.5-9] vs 6 [2.5-8], p = 0.396) and number of days of breakthrough opioid use (5 [3-8] vs 4 [2.5-5.5], p = 0.233). Following implementation of an individualized pain plan, there was an increase in median average MME per day (65.94 [53.1-97.7] vs 82.85 [41-114.3], p = 0.844). Median length of stay and days on scheduled opioids remained the same. Conclusions: This study demonstrated that use of individualized pain plans in a small population of patients with SCD might result in decreased pain scores and decreased days on breakthrough opioids.
dc.eprint.versionFinal published version
dc.identifier.citationArends AM, Perez A, Wilder C, Jacob SA. Evaluation of Individualized Pain Plans for Children With Sickle Cell Disease Admitted for Vaso-occlusive Crisis at Riley Hospital for Children. J Pediatr Pharmacol Ther. 2022;27(4):312-315. doi:10.5863/1551-6776-27.4.312
dc.identifier.urihttps://hdl.handle.net/1805/41947
dc.language.isoen_US
dc.publisherAllen Press
dc.relation.isversionof10.5863/1551-6776-27.4.312
dc.relation.journalThe Journal of Pediatric Pharmacology and Therapeutics
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectAnalgesics
dc.subjectOpioid
dc.subjectAnemia
dc.subjectSickle cell
dc.subjectChild
dc.subjectHospitalization
dc.subjectLength of stay
dc.subjectMME
dc.subjectPain management
dc.titleEvaluation of Individualized Pain Plans for Children With Sickle Cell Disease Admitted for Vaso-occlusive Crisis at Riley Hospital for Children
dc.typeArticle
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088439/
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Arends2022Evaluation-PP.pdf
Size:
485.65 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: